Celltrion’s head of strategy and operations, Ho Ung Kim, told reporters this week that the intravenous Herzuma could be launched at as much as a 50% discount to a subcutaneously administered presentation of the reference Herceptin.
Celltrion announced on Tuesday that the European Commission (EC) has granted a marketing authorization for Herzuma, Celltrion’s biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive early breast cancer, metastatic breast cancer, or metastatic gastric cancer.
Final approval of the biosimilar follows a December 2017 positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use. The EC’s decision allows Herzuma to be marketed in the 28 member states of the European Union, as well as in Norway, Liechtenstein, and Iceland.
“The development of [biosimilars] is of great importance in the field of oncology, and has the potential to enrich our therapeutic arsenal against a variety of diseases and to increase patients’ accessibility to innovative drugs at a more affordable price,” said Woo Sung Kee, CEO of Celltrion.
While a launch date for the biosimilar has not yet been announced, a representative from Celltrion Healthcare, Celltrion’s marketing arm, told Korean media in 2017 that Herzuma could be launched in Europe as soon as 3 months following EC approval. Celltrion’s head of strategy and operations, Ho Ung Kim, told reporters this week that the intravenous Herzuma could be launched at as much as a 50% discount to a subcutaneously administered presentation of the reference Herceptin.
Celltrion also filed a Biologics License Application for the trastuzumab biosimilar with the FDA in July 2017, but recent regulatory challenges have put a potential US approval date into question; while a regulatory decision on Herzuma was expected in March 2018, Celltrion received a warning letter from the FDA on January 30 that raised issues with the company’s manufacturing practices.
In a February 1 statement on the letter, Celltrion said that the warning did not impact the company’s ability to make its biosimilar infliximab, Inflectra, but did not disclose how the warning would impact Herzuma. However, Celltrion’s partner, Teva, told investors that FDA approval of both Herzuma and a proposed rituximab biosimilar would likely be delayed while Celltrion remediates the issues at the facility.
The company also faces ongoing legal challenges for Herzuma in the United States; Celltrion and Teva have filed a lawsuit against Genentech (sponsor of the reference Herceptin) in a California district court, seeking a declaratory judgment that 38 patents covering Herceptin are invalid, unenforceable, or not infringed by Celltrion’s product. The patents include those addressing methods of production, dosage, methods of treatment, and extending time to disease progression, among others.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
2 Commerce Drive
Cranbury, NJ 08512